madman
Super Moderator
* Over the past decade, 4 BPH stents have received FDA approval, with 2 nitinol-based stents—Zenflow and ProVee—entering the market in late 2025, marking a significant expansion of office-based treatment options.
* Zorn places the rise of MISTs within the broader context of an aging male population, increasing BPH prevalence, and workforce limitations in urology, emphasizing the need for fast, durable, and well-tolerated interventions that preserve sexual and ejaculatory function.
Kevin C. Zorn, MD, FRCSC, FACS, outlines notable advances in the management of benign prostatic hyperplasia over the past year.
In a recent interview with Urology Times®, Kevin C. Zorn, MD, FRCSC, FACS, outlined notable advances in the management of benign prostatic hyperplasia (BPH) over the past year. Zorn also looks ahead to what developments are expected in 2026.
Zorn is a urologist at BPH Canada in Montreal.
www.urologytimes.com
Zorn begins the discussion by reviewing the major advances in minimally invasive surgical therapies (MISTs) for BPH, with a particular focus on the rapid evolution of urethral stent technology. Over the past decade, 4 BPH stents have received FDA approval, with 2 nitinol-based stents—Zenflow and ProVee—entering the market in late 2025, marking a significant expansion of office-based treatment options.
Zorn places the rise of MISTs within the broader context of an aging male population, increasing BPH prevalence, and workforce limitations in urology, emphasizing the need for fast, durable, and well-tolerated interventions that preserve sexual and ejaculatory function.
Looking ahead, Zorn highlights the growing complexity of treatment selection as the MIST landscape expands, underscoring the need for better patient-specific decision tools. Future directions include leveraging advanced imaging, urethral geometry, tissue elasticity, and AI-driven modeling to match patients with the optimal stent or therapy. Additionally, new digital health tools such as smartphone-based uroflowmetry apps may improve diagnostic accuracy, workflow efficiency, and early detection of disease progression.
Overall, 2025 represents a pivotal year for BPH management, with expanding options that promise faster recovery, preserved function, and greater personalization of care.
* Zorn places the rise of MISTs within the broader context of an aging male population, increasing BPH prevalence, and workforce limitations in urology, emphasizing the need for fast, durable, and well-tolerated interventions that preserve sexual and ejaculatory function.
Kevin C. Zorn, MD, FRCSC, FACS, outlines notable advances in the management of benign prostatic hyperplasia over the past year.
In a recent interview with Urology Times®, Kevin C. Zorn, MD, FRCSC, FACS, outlined notable advances in the management of benign prostatic hyperplasia (BPH) over the past year. Zorn also looks ahead to what developments are expected in 2026.
Zorn is a urologist at BPH Canada in Montreal.
Kevin Zorn, MD, highlights key BPH advances of 2025 | Urology Times
Kevin C. Zorn, MD, FRCSC, FACS, outlines notable advances in the management of benign prostatic hyperplasia over the past year.
Zorn begins the discussion by reviewing the major advances in minimally invasive surgical therapies (MISTs) for BPH, with a particular focus on the rapid evolution of urethral stent technology. Over the past decade, 4 BPH stents have received FDA approval, with 2 nitinol-based stents—Zenflow and ProVee—entering the market in late 2025, marking a significant expansion of office-based treatment options.
Zorn places the rise of MISTs within the broader context of an aging male population, increasing BPH prevalence, and workforce limitations in urology, emphasizing the need for fast, durable, and well-tolerated interventions that preserve sexual and ejaculatory function.
Looking ahead, Zorn highlights the growing complexity of treatment selection as the MIST landscape expands, underscoring the need for better patient-specific decision tools. Future directions include leveraging advanced imaging, urethral geometry, tissue elasticity, and AI-driven modeling to match patients with the optimal stent or therapy. Additionally, new digital health tools such as smartphone-based uroflowmetry apps may improve diagnostic accuracy, workflow efficiency, and early detection of disease progression.
Overall, 2025 represents a pivotal year for BPH management, with expanding options that promise faster recovery, preserved function, and greater personalization of care.
